- 作者：Adam S. Garden ; MD&lowast ; ; agarden@mdanderson.org ; Lei Dong ; PhD&dagger ; ; William H. Morrison ; MD&lowast ; ; Erich M. Stugis ; MD ; MPH§ ; ; ¡¬ ; Bonnie S. Glisson ; MD&Dagger ; ; Steven J. Frank ; MD&lowast ; ; Beth M. Beadle ; MD ; PhD&lowast ; ; Gary B. Gunn ; MD&lowast ; ; David L. Schwartz ; MD¶ ; ; Merill S. Kies ; MD&lowast ; ; &Dagger ; ; Randal S. Weber ; MD§ ; ; K. Kian Ang ; MD ; PhD&lowast ; ; David I. Rosenthal ; MD&lowast ;
- 刊名：International Journal of Radiation Oncology*Biology*Physics
- 出版年：2013
- 出版时间：15 March, 2013
- 年：2013
- 卷：85
- 期：4
- 页码：941-947
- 全文大小：212 K
Purpose
To report mature results of a large cohort of patients diagnosed with squamous cell carcinoma of the oropharynx who were treated with intensity modulated radiation therapy (IMRT).Methods and Materials
The database of patients irradiated at The University of Texas, M.D. Anderson Cancer Center was searched for patients diagnosed with oropharyngeal cancer and treated with IMRT between 2000 and 2007. A retrospective review of outcome data was performed.
Results
The cohort consisted of 776 patients. One hundred fifty-nine patients (21 % ) were current smokers, 279 (36 % ) former smokers, and 337 (43 % ) never smokers. T and N categories and American Joint Committee on Cancer group stages were distributed as follows: T1/x, 288 (37 % ); T2, 288 (37 % ); T3, 113 (15 % ); T4, 87 (11 % ); N0, 88(12 % ); N1/x, 140 (18 % ); N2a, 101 (13 % ); N2b, 269 (35 % ); N2c, 122 (16 % ); and N3, 56 (7 % ); stage I, 18(2 % ); stage II, 40(5 % ); stage III, 150(19 % ); and stage IV, 568(74 % ). Seventy-one patients (10 % ) presented with nodes in level IV. Median follow-up was 54 months. The 5-year overall survival, locoregional control, and overall recurrence-free survival rates were 84 % , 90 % , and 82 % , respectively. Primary site recurrence developed in 7 % of patients, and neck recurrence with primary site control in 3 % . We could only identify 12 patients (2 % ) who had locoregional recurrence outside the high-dose target volumes. Poorer survival rates were observed in current smokers, patients with larger primary (T) tumors and lower neck disease.
Conclusions
Patients with oropharyngeal cancer treated with IMRT have excellent disease control. Locoregional recurrence was uncommon, and most often occurred in the high dose volumes. Parotid sparing was accomplished in nearly all patients without compromising tumor coverage.